Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 09/724.685 Application Number Filing Date 11-28-2000 INFORMATION DISCLOSURE First Named Inventor Steven G. Reed STATEMENT BY APPLICANT Art Unit 1645 (Use as many sheets as necessary) Examiner Name Rodney P. Swartz Sheet 32 GSK006C13/CRX411C13 11 Attorney Docket Number

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
initiais:		Number - Kind Code ^{2 (f known)}		- ''	Figures Appear
	151	US-6,977,069	12/20/2005	Reed et al.	
	152	US-7,026,465	04/11/2006	Skeiky et al	
	153	US-7,064,195	06/20/2006	Skeiky et al	
	154	US-7,087,713	08/08/2006	Campos-Neto et al.	
	155	US-7,335,369	02/26/2008	Reed et al.	
	156	US-7,678,375	03/16/2010	Skeiky et al.	
	157	US-7,691,993	04/06/2010	Skeiky et al	
	158	US-2006/0193876	08/31/2006	Skeiky et al.	
	159	US-2009/0018095	01/15/2009	Skeiky et al	
	160	US-2009/0017077	01/15/2009	Reed et al.	
	161	US-2008/0199405	08/21/2008	Reed et al.	
	162	US-2009/0306195	12/10/2009	Skeiky et al.	
	163	US-2007/0141087	06/21/2007	Reed et al.	
	164	US-2007/0054336	03/08/2007	Campos-Neto et al.	
	165	US-2008/0176798	07/24/2008	Campos-Neto et al	
	166	US-2009/0022742	01/22/2009	Campos-Neto et al	
	167	US-2009/0281168	11/12/2009	Reed et al.	
	168	US-2008/0269151	10/30/2009	Skeiky et al.	
	169	US-2009/0306195	10/10/2009	Skeiky et al	
	170	US-2006/0193876	08/31/2008	Skeiky et al.	
	171	US-2009/0018095	01/15/2009	Skeiky et al	
	172	US-2008/0317716	12/25/2008	Skeiky et al.	
	173	US-2010/0015096	01/21/2010	Skeiky et al	
	174	US-2010/0183657	07/22/2010	Skeiky et al.	
	175	US-2010/0183677	07/22/2010	Skeiky et al	

	Examiner Signature		Date Considered	
U		tribel it reference accordanced substitutes as not distribute in accordance with MDED 80.		

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO of process) an application. Confidentially is governed by 58 U.S. C. 22 and 37 CFR 1.14 This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cher Information USPTO. Sent the complete this form and/or suggestions for reducing this burden, should be sent to the Cher Information USPTO. Sent 186, Alexandria, VA 2231-3450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND/OTO: Commissioner for Pleatints, P.O. Dos 1450, Navandria, VA 2231-3450.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	E			Complete if Known		
Sub	stitute for form 1449A/PTO			Application Number	09/724,685	
	NEODMATION DISCI	00	HIDE	Filing Date	11-28-2000	
INFORMATION DISCLOSURE				First Named Inventor	Steven G. Reed	
۶	STATEMENT BY APP	LIC	ANI	Art Unit	1645	
	(Use as many sheets as nece	ssary)		Examiner Name	Rodney P. Swartz	
Sheet	12	of	32	Attorney Docket Number	GSK006C13/CRX411C13	

EODEIGN DATENT DOCUMENTS

		FORE	EIGN PATENT DO	CUMENTS	T	_
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	T
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	Ľ
	176	WO 99/09186 Part 2	02/25/1999	Gicquel		
	177	WO 99/09186 Part 3	02/25/1999	Gicquel		
	178	WO 99/09186 Part 4	02/25/1999	Gicquel		E
	179	WO 99/09186 Part 5	02/25/1999	Gioquel		
	180	WC99/33488	07/18/1999	Dalemans et al.		
	181	WO 99/42076 Part 1	08/26/1999	Reed et al.		
	182	WO 99/42076 Part 2	08/26/1999	Reed et al.		Е
	183	WO 99/42076 Part 3	08/26/1999	Reed et al.		
	184	WO 99/42076 Part 4	08/26/1999	Reed et al.		
	185	WO 99/42118 Part 1	08/26/1999	Reed et al.		
	186	WO 99/42118 Part 2	08/26/1999	Reed et al.		
	187	WO 99/42118 Part 3	08/26/1999	Reed et al.		Г
	188	WO 99/42118 Part 4	08/26/1999	Reed et al.		Е
	189	WO 99/42118 Part 5	08/26/1999	Reed et al		
	190	WO/99/51748 Part 1	10/14/1999	Skeiky et al		Г
	191	WO/99/51748 Part 2	10/14/1999	Skeiky et al.		Г
	192	WO 99/5254900	10/21/1999	Friede et al.		Г
	193	WO 00/09159	02/24/2000	Kensil et al.		Е
	194	WO 01/034803 Part 1	05/17/2001	Holloway et al		Г
	195	WO 01/034803 Part 1	05/17/2001	Holloway et al.		Г
	196	WO 01/090152 Part 1	11/29/2001	Frudakis et al.		Г
	197	WO 01/090152 Part 2	11/29/2001	Frudakis et al.		Ε
	198	WO 01/090152 Part 3	11/29/2001	Frudakis et al.		Г
	199	WO 01/090152 Part 4	11/29/2001	Frudakis et al.		Г
	200	WO 01/24820 Part 1	04/12/2001	Skeiky et al		Г

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.cov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. *Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information values of dispays a valid CMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

Filing Date 11-28-2000

First Named Inventor Steven G. Reed

INFORMATION DISCLOSURE	Filing Date	11-28-2000
STATEMENT BY APPLICANT	First Named Inventor	Steven G. Reed
Art Unit	1645	
Examiner Name	Rodney P. Swartz	
Attorney Docket Number	GSKO06C13/GRX411C13	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No 1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	201	WO 01/24820 Part 2	04/12/2001	Skeiky et al.	or Holovani rigoroo rippodi	\top
	202	WO 01/24820 Part 3	04/12/2001	Skeiky et al.		Т
	203	WO 01/34802 Part 1	05/17/2001	Xu et al.		т
	204	WO 01/34802 Part 2	05/17/2001	Xu et al		
	205	WO 01/34802 Part 3	05/17/2001	Xu et al		
	206	WO 01/34802 Part 4	05/17/2001	Xu et al.		
	207	WO 01/34802 Part 5	05/17/2001	Xu et al.		
	208	WO 01/51633 Part 1	07/19/2001	Xu et al.		г
	209	WO 01/51633 Part 2	07/19/2001	Xu et al		
	210	WO 01/51633 Part 3	07/19/2001	Xu et al		Г
	211	WO 01/51633 Part 4	07/19/2001	Xu et al		
	212	WO 01/51633 Part 5	07/19/2001	Xu et al		
	213	WO 01/51633 Part 6	07/19/2001	Xu et al		
	214	WO 01/51633 Part 7	07/19/2001	Xu et al.		
	215	WO 01/51633 Part 8	07/19/2001	Xu et al		
	216	WO 01/51633 Part 9	07/19/2001	Xu et al		
	217	WO 01/62893 Part 1	08/30/2001	Campos-Neto et al.		
	218	WO 01/62893 Part 2	08/30/2001	Campos-Neto et al.		
	219	WO 01/62893 Part 3	08/30/2001	Campos-Neto et al.		
	220	WO 01/73032 Part 1	10/04/2001	Xu et al.		
	221	WO 01/73032 Part 2	10/04/2001	Xu et al		
	222	WO 01/73032 Part 3	10/04/2001	Xu et al		
	223	WO 01/73032 Part 4	10/04/2001	Xu et al		
	224	WO 01/73032 Part 5	10/04/2001	Xu et al		
	225	WO 01/73032 Part 6	10/04/2001	Xu et al.		Г

Examiner	Date	
Signature	Considered	

[&]quot;EXAMINET: Initial if reference considered, whether or not citation is in conformance with MPEP 000. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant "Applicants' unique citation designation number (polition) see Kinds Codes of USPTO Patent Documents as <u>www.upio.org</u> or MPEP 001.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST3)." For Japanese patent documents, the includation of the year of the regind or the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the year of the regind of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English Inaquage Translation is statched."

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO be proceed) an application. Confidentially is governed by 36 U.S. C. 22 and 37 CFR 1.14. This collection is estimated to take 2 house to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestons for reducing this burden, should be sent to the Chief Information CT. US. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1469, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Pleatins, P.O. Des 1496, Newsondria, VA. 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	09/724,685		
I INF	ORMATION DISC	er os	SURF	Filing Date	11-28-2000		
	ATEMENT BY AF			First Named Inventor	Steven G. Reed		
ויי ן	AIEWENI DI AF	FLIC	ZANI	Art Unit	1645		
	(Use as many sheets as ne	cessary,)	Examiner Name	Rodney P. Swartz		
Sheet	14	of	32	Attorney Docket Number	GSK006C13/CRX411C13		

NON PATENT LITERATURE DOCUMENTS					
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т		
	226	HIGGINS and SHARP, "Fast and sensitive multiple sequence alignments on a microcomputer," Cabios 5:151-153 (1989)			
	227	HOBBS, McGraw Hill Yearbook of Science and Technology, pages 191-96 (1992)			
	228	HORN, et al., "Synthesis of oligonucleotides on cellulose," Nucl. Acids Res. Symposia Series, pp. 225-232 (1980)			
	229	JACOBS, "Advances in mycobacterial genetics: new promises for old diseases," Immunobiology 184(2-3):147-156 (1992)			
	230	JURCEVIC, et al., "T cell responses to a mixture of Mycobacterium tuberculosis peptide with complementary HLA-DR binding profiles," Clinical and Experimental Immunology 105(3):416-421 (1996)			
	231	KALINOWSKI, et al., "Genetic and biochemical analysis of the aspartokinase from Corynebacterium glutamicum," Molecular Microbiology 5:1197-1204 (1991)			
	232	KASS-EISLER, et al., "Quantitative determination of Adenoviral-mediated gene delivery to rat cardiac myocytes in vitro and in vivo." PNAS USA 90:11498–11502 (1993)			
	233	KARLIN and ALTSCHUL, "Applications and statistics for multiple high-scoring segments in molecular sequences," PNAS USA 90: 3873 – 5787 (1993)			
	234	KAUFMANN, et al., "Vaccination against tuberculosis and leprosy," Immunobiology 184(2-3): 208-229 (1992)			
	235	KHANOLKAR-YOUNG, et al., "Results of the Third Immunology of Tuberculosis Anitmycobacterial Monoclonal Antibody Workshop Infection and Immunity 60(9):3925-927 (1992)			

Examiner	Date	
Signature	Concidered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1-98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. O----I-4- # K-----

Substitute for form 1449B/PTO				Complete ii Known			
				Application Number	09/724,685		
I INF	ORMATION DISC	er os	SURF	Filing Date	11-28-2000		
	ATEMENT BY AF			First Named Inventor	Steven G. Reed		
31/	ALEMENT DI AF	FLIC	ZANI	Art Unit	1645		
	(Use as many sheets as ne	cessary,)	Examiner Name	Rodney P. Swartz		
Sheet	15	of	32	Attorney Docket Number	GSK006C13/CRX411C13		

NON PATENT LITERATURE DOCUMENTS					
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Γ		
	236	KOHLER and MILSTEIN, "Continuous cultures of fused cells secreting antibodies of predefined sequence," Nature 256:495-497 (1975)	Ī		
	237	KOLLS, "Prolonged and effective blockade of TNF activity through Adenoviral-mediated gene transfer," PNAS USA 91: 215-219 (1994)	-		
	238	KOZAK, "Comparison of Initiation of Protein Synthesis in Procaryotes, Eucaryotes, and Organelles," Microbiological Review, pp. 1-45 (1983)	ŀ		
	239	KROLL, et al., "A Multifunctional Prokaryotic Protein Expression System: Overproduction, Affinity Purification, and Selective Detection," DNA Cell Biol. 12.441-453 (1993)	ľ		
	240	LABOUESSE, et al., "Conformational changes in enzyme catalysis," Biochemistry 48:2137-2145 (1962)	l		
	241	LAUNOIS, et al., "T-Cell Epitope Mapping of the Major Secreted Mycobacterial Antigen AG85A in Tuberculosis and Leprosy," Infection and Immunity 62:3679-97 (1994)			
	242	LEAC, et al., "Immunological and functional characterization of proteins of the Mycobacterium tuberculosis antigen 85 complex using synthetic peptides," J. Gen. Microbiol. 139:1543-1549 (1993)	ľ		
	243	LEWIN, Genes IV, Oxford University Press, pp. 124-26 (1990)	-		
	244	LEWINSOHN, et al., "Characterization of HumanCD8+ T Cells Reactive with Mycrobacterium tuberculosis- infected Antigen-presenting Cells," J. Exp. Med. 187(10):1633-1640 (1998)			
	245	LI, et al., "Important Role of the Amino Acid Attached to tRNA in Formylation and in Initiation of Protein Synthesis in Escherichia coli," J. Biol. Chem., 271:1022-1028 (1996)	-		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	09/724,685		
INFORMATION DISCLOSURE				Filing Date	11-28-2000		
STATEMENT BY APPLICANT				First Named Inventor	Steven G. Reed		
31/	STATEMENT BY APPLICANT			Art Unit	1645		
	(Use as many sheets as ne	cessary)		Examiner Name	Rodney P. Swartz		
Sheet 16 of 32		32	Attorney Docket Number	GSK006C13/CRX411C13			

NON PATENT LITERATURE DOCUMENTS							
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T				
	246	LJUNGOVIST, et al., "Antibody Responses Against Mycobacterium Tuberculosis in 11 Strains of Inbred Mico Novel Monoclonal Antibody Specificities Generated by Fusions Using Spleens from BALB B10 and CBA-J Mice," Intections and Immunity 46(6):1984-96 (1988)					
	247	LOGAN and SHENK, "Advenovirus tripartite leader sequence enhances translation of mRNAs late after infection," PNAS USA 81: 365 –3659 (1984)					
	248	LOWY, et al., "Isolation of transforming DNA: Cloning the Hamster aprt Gene," Cell 22:817-23 (1990)					
	249	MADDOX, et al., "Elevated Serum Levels in Human Pregnancy of a Molecule immunochemically similar to Eosinophil Granule Major Basic Protein," J. Exp. Med. 158:1211-1216 (1983)					
	250	MAHVI, et al., "DNA Cancer Vaccines—A Gene Gun Approach," Imm. and Cell Bio. 75: 456-460 (1997)					
	251	MANCA, et al., "Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis," Infection and Immunity 65(1):16-23 (1997)					
	253	MARATEA,et al., "Deletion and fusion analysis of phage phi-X-174 lysis gene E," Gene 40:39-46 (1985)					
	254	MATSUMOTO, et al., "Clonling and Sequencing of a Unique Antigen MPT70 from Mycobacterium tuberculosis H37Rv and Expression in BCG Using E. coll-Mycobacteria Shuttle Vector," Scand. J. Immunol. 41:281-287 (1995)					
	255	MERRIFIELD, "Solid Phase Peptide Synthesis," J. Am. Chem. Soc. 85:2149 – 2146 (1963)					
	256	MOSMANN and COFFAN, "Th1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," Ann. Rev. Immunol. 7:145-173 (1989)					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	09/724,685		
INFORMATION DISCLOSURE				Filing Date	11-28-2000		
STATEMENT BY APPLICANT				First Named Inventor	Steven G. Reed		
'''ا	(Use as many sheets as necessary)			Art Unit	1645		
				Examiner Name	Rodney P. Swartz		
Sheet 17 c		of	32	Attorney Docket Number	GSK006C13/CRX411C13		

NON PATENT LITERATURE DOCUMENTS							
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т				
	257	MURPHY, et al., "Genetic construction, expression and melanoma-selective cytotoxicity of a diphtheria toxin- related alpha-melanccyte stimulating hormone fusion protein," PNAS USA 83: 828-8262 (1986)					
	258	NAGAI, et al., "Isolation and Partial Characterization of Major Protein Antigens in the Culture Fluid of Mycobacterium tuberculosis," Infection and Immunity 59(1):372-382 (1991)					
	259	NEEDLEMAN and WUNSCH, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," J. Mol. Biol. 48:443 (1970)					
	260	NEWPORT, et al., "A Mutation in the Interferon-γ-Receptor Gene and Susceptibility to Mycobacterial Infection," New Eng. J. of Medicine 335(26):1941-1949 (1996)					
	261	NOSOH, et al., Protein Stability and Stabilization through Protein Engineering, chap. 7, p. 197 (1991)	-				
	262	OETTINGER, et al., "Cloning and B-cell-epitope mapping of MPT64 from Mycobacterium tuberculosis H37Rv," Infection and Immunity 62(5):2059-2064 (1994)					
	263	ORTEGA, et al., "Single-step purification on DEAE-sephacel of recombinant polypeptides produced in Escherichia coll," Biofechnology 10.795-798 (1992)					
	264	PAL, et al., "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis", Infection and immunity 60(11), 4781-4792 (1998).	-				
	265	PARKER, et al., "Targeted Gene Walking Polymerase Chain Reactions," Nuc. Acids Res. 19: 3055-60 (1991)					
	266	PAUL, Fundamental Immunology, chap. 8, 243 – 247 (1993)	-				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for form 1449B/PTO Application Number 09/724,685 11-28-2000 Filing Date

INFORMATION DISCLOSURE First Named Inventor Steven G. Reed STATEMENT BY APPLICANT Art Unit 1645 (Use as many sheets as necessary) Examiner Name Rodney P. Swartz Sheet of Attorney Docket Number GSK006C13/CRX411C13 18 32

	Examine Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book. T ²							
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ĺ					
	267	PORATH, et al., "Immobilized Metal Ion Affinity Chromatography," Proto Exp. Purif. 3:263-281 (1992)						
	268	POUTHIER, et al., *Anti-A60 immunoglobulin G in the serodiagnosis of tuberculosis in HIV-seropositive and seronegative patients, *AIDS 8(9):1277-80 (1994)	ľ					
	269	REED, et al., "Tuberculosis vaccine development: from mouse to man," Microbes and Infection 7(5-6):992-31 (2005)						
	270	REED, et al., "Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys," PNAS 106(7):2301-06 (2009)	ľ					
	271	RHODES, et al., "Transformations of Maize by the Electroporation of Embryos," Methods Mol. Biol. 55:121-131 (1995)	ľ					
	272	RIVEAU, et al., "Synthetic peptide vaccines against peptides and biological mediators," Trends in Pharmacological Sciences 11:194-198 (1990)						
	273	ROBERTS, et al., "Prediction of HIV peptide epitopes by a novel algorithm," AIDS Research and Human Retroviruses 12:593-610 (1996)	ľ					
	274	ROMAIN, et al., "solation of a proline-rich mycobacterial protein eliciting delayed-type hypersensitivity reactions only in guinea pigs immunized with living mycobacteria," PNAS USA 90.5322-5326 (1993)	ŀ					
	275	ROMANO, et al., "Immunogenicity and protective efficacy of tuberculosis subunit vaccines expression PPE44 (Rv2770c)," Vaccine, 26(48):6053-63 (2008)	l					
	276	ROLLAND, "From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery," Crit. Rev. Therap. Drug Carrier Systems 15:143-198 (1998)	r					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.